Hearing EF Hutton Initiates Coverage On Bone Biologics With Buy Rating And $2.25 Price Target
BenzingaJun 1, 2023 04:52
EF Hutton Reiterates Buy on Bone Biologics, Maintains $2.25 Price Target
BenzingaApr 13, 2023 19:05
EF Hutton Reiterates Buy on Bone Biologics, Maintains $2.25 Price Target
BenzingaApr 3, 2023 22:10
No Data
No Data